Indolent peritoneal mesothelioma: PI3K-mTOR inhibitors as a novel therapeutic strategy.

about

Malignant peritoneal mesothelioma: clinical aspects, and therapeutic perspectives

P2860

Q58541846-2DB3EF9B-A7AD-42B1-BE2A-49DA82B87B74

P2860

Indolent peritoneal mesothelioma: PI3K-mTOR inhibitors as a novel therapeutic strategy.

Item

http://www.wikidata.org/entity/Q53990140

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh

2017年學術文章

@zh-hant

name

Indolent peritoneal mesothelioma: PI3K-mTOR inhibitors as a novel therapeutic strategy.

@en

Indolent peritoneal mesothelioma: PI3K-mTOR inhibitors as a novel therapeutic strategy.

@nl

type

Item

label

Indolent peritoneal mesothelioma: PI3K-mTOR inhibitors as a novel therapeutic strategy.

@en

Indolent peritoneal mesothelioma: PI3K-mTOR inhibitors as a novel therapeutic strategy.

@nl

prefLabel

Indolent peritoneal mesothelioma: PI3K-mTOR inhibitors as a novel therapeutic strategy.

@en

Indolent peritoneal mesothelioma: PI3K-mTOR inhibitors as a novel therapeutic strategy.

@nl

P1476

Indolent peritoneal mesothelioma: PI3K-mTOR inhibitors as a novel therapeutic strategy

@en

P2093

Chiara Della-Pepa

http://www.w3.org/2001/XMLSchema#string

Cristina Migali

http://www.w3.org/2001/XMLSchema#string

Johann S de Bono

http://www.w3.org/2001/XMLSchema#string

Nina Tunariu

http://www.w3.org/2001/XMLSchema#string

Saoirse O Dolly

http://www.w3.org/2001/XMLSchema#string

Stanley B Kaye

http://www.w3.org/2001/XMLSchema#string

Steve Hazell

http://www.w3.org/2001/XMLSchema#string

Susana Banerjee

http://www.w3.org/2001/XMLSchema#string

P2860

Phase I Study of Apitolisib (GDC-0980), Dual Phosphatidylinositol-3-Kinase and Mammalian Target of Rapamycin Kinase Inhibitor, in Patients with Advanced Solid Tumors.

Sensitive and specific new enzyme-linked immunosorbent assay for N-ERC/mesothelin increases its potential as a useful serum tumor marker for mesothelioma

Malignant mesothelioma: facts, myths, and hypotheses

Molecular pathways: targeting mechanisms of asbestos and erionite carcinogenesis in mesothelioma

Well-differentiated papillary mesothelioma of the pleura: a series of 24 cases.

Guidelines for pathologic diagnosis of malignant mesothelioma: 2012 update of the consensus statement from the International Mesothelioma Interest Group.

The nuclear deubiquitinase BAP1 is commonly inactivated by somatic mutations and 3p21.1 losses in malignant pleural mesothelioma.

Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma.

Malignant peritoneal mesothelioma.

Epidemiology of peritoneal mesothelioma: a review.

P304

e000101

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1136/ESMOOPEN-2016-000101

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Shelize Khakoo

P577

2017-04-12T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28761723

http://www.w3.org/2001/XMLSchema#string

P932

5519796

http://www.w3.org/2001/XMLSchema#string

Indolent peritoneal mesothelioma: PI3K-mTOR inhibitors as a novel therapeutic strategy.

about

P2860

P2860

Indolent peritoneal mesothelioma: PI3K-mTOR inhibitors as a novel therapeutic strategy.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P932